| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 31 | 2016 | 1536 | 1.650 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 22 | 2014 | 468 | 1.620 |
Why?
|
| Adenocarcinoma | 12 | 2014 | 475 | 1.070 |
Why?
|
| Leukemia, Myeloid, Acute | 7 | 2012 | 116 | 1.030 |
Why?
|
| Prostatic Neoplasms | 15 | 2012 | 778 | 0.960 |
Why?
|
| DNA Methylation | 14 | 2016 | 193 | 0.860 |
Why?
|
| Antineoplastic Agents | 16 | 2016 | 1070 | 0.820 |
Why?
|
| Humans | 204 | 2016 | 68618 | 0.820 |
Why?
|
| Aged | 88 | 2016 | 14862 | 0.760 |
Why?
|
| Clinical Trials, Phase I as Topic | 6 | 2014 | 26 | 0.750 |
Why?
|
| Lung Neoplasms | 15 | 2013 | 1173 | 0.750 |
Why?
|
| Female | 136 | 2016 | 38074 | 0.710 |
Why?
|
| Middle Aged | 98 | 2016 | 21147 | 0.710 |
Why?
|
| Male | 108 | 2016 | 37321 | 0.590 |
Why?
|
| Autistic Disorder | 3 | 2007 | 77 | 0.590 |
Why?
|
| Cholecalciferol | 3 | 2012 | 143 | 0.580 |
Why?
|
| CD8-Positive T-Lymphocytes | 9 | 2016 | 266 | 0.580 |
Why?
|
| Aged, 80 and over | 40 | 2016 | 4848 | 0.580 |
Why?
|
| Neoplasms | 12 | 2014 | 1667 | 0.550 |
Why?
|
| Biomarkers, Tumor | 6 | 2011 | 508 | 0.540 |
Why?
|
| Gene Expression Regulation, Neoplastic | 14 | 2016 | 756 | 0.540 |
Why?
|
| Quinolones | 4 | 2011 | 60 | 0.540 |
Why?
|
| Models, Statistical | 6 | 2011 | 448 | 0.520 |
Why?
|
| Health Education | 4 | 2012 | 279 | 0.510 |
Why?
|
| Biology | 1 | 2015 | 14 | 0.500 |
Why?
|
| Education, Graduate | 1 | 2015 | 30 | 0.490 |
Why?
|
| Adult | 77 | 2016 | 21403 | 0.480 |
Why?
|
| Faculty | 1 | 2015 | 56 | 0.480 |
Why?
|
| Breath Holding | 1 | 2014 | 8 | 0.470 |
Why?
|
| Spirometry | 1 | 2014 | 47 | 0.470 |
Why?
|
| Neoplasm Recurrence, Local | 10 | 2011 | 446 | 0.460 |
Why?
|
| Receptors, Antigen, T-Cell | 6 | 2016 | 135 | 0.460 |
Why?
|
| Dietary Supplements | 4 | 2012 | 332 | 0.460 |
Why?
|
| Schools, Medical | 1 | 2015 | 157 | 0.450 |
Why?
|
| Respiration | 1 | 2014 | 91 | 0.450 |
Why?
|
| Coronary Circulation | 1 | 2014 | 136 | 0.440 |
Why?
|
| Cell Line, Tumor | 23 | 2016 | 1851 | 0.430 |
Why?
|
| Vitamin D Deficiency | 4 | 2012 | 292 | 0.410 |
Why?
|
| Pharmacogenetics | 2 | 2013 | 47 | 0.410 |
Why?
|
| Vitamin D | 4 | 2012 | 516 | 0.400 |
Why?
|
| Carcinoma, Squamous Cell | 7 | 2016 | 629 | 0.400 |
Why?
|
| Lymph Nodes | 4 | 2016 | 258 | 0.400 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2012 | 931 | 0.390 |
Why?
|
| Coronary Vessels | 1 | 2014 | 313 | 0.390 |
Why?
|
| Smoking | 7 | 2016 | 1452 | 0.380 |
Why?
|
| Taxoids | 8 | 2011 | 41 | 0.380 |
Why?
|
| Perception | 1 | 2012 | 189 | 0.370 |
Why?
|
| Dose-Response Relationship, Drug | 12 | 2014 | 1745 | 0.360 |
Why?
|
| Indians, North American | 1 | 2010 | 64 | 0.360 |
Why?
|
| Neutropenia | 2 | 2010 | 72 | 0.360 |
Why?
|
| Pancreatic Neoplasms | 5 | 2014 | 332 | 0.360 |
Why?
|
| Health Promotion | 2 | 2012 | 407 | 0.350 |
Why?
|
| Vancomycin Resistance | 1 | 2010 | 18 | 0.350 |
Why?
|
| Communication Disorders | 2 | 2007 | 12 | 0.350 |
Why?
|
| Survival Rate | 17 | 2012 | 1056 | 0.340 |
Why?
|
| Colonic Neoplasms | 4 | 2016 | 299 | 0.340 |
Why?
|
| Fever | 1 | 2010 | 96 | 0.330 |
Why?
|
| Head and Neck Neoplasms | 6 | 2016 | 561 | 0.330 |
Why?
|
| Gene Expression Profiling | 7 | 2014 | 498 | 0.330 |
Why?
|
| Doxorubicin | 7 | 2012 | 231 | 0.330 |
Why?
|
| Melanoma | 3 | 2016 | 335 | 0.330 |
Why?
|
| Prostate-Specific Antigen | 10 | 2011 | 138 | 0.330 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 5 | 2014 | 101 | 0.320 |
Why?
|
| Program Evaluation | 2 | 2010 | 502 | 0.320 |
Why?
|
| Developmental Disabilities | 2 | 2007 | 119 | 0.320 |
Why?
|
| Maximum Tolerated Dose | 6 | 2012 | 41 | 0.320 |
Why?
|
| Disease-Free Survival | 12 | 2016 | 349 | 0.310 |
Why?
|
| Gene Expression | 5 | 2015 | 770 | 0.310 |
Why?
|
| Neoplasm Staging | 13 | 2016 | 800 | 0.310 |
Why?
|
| Carcinoma, Lobular | 4 | 2011 | 20 | 0.300 |
Why?
|
| Bacteremia | 1 | 2010 | 155 | 0.300 |
Why?
|
| Nonverbal Communication | 1 | 2007 | 4 | 0.300 |
Why?
|
| Socialization | 1 | 2007 | 13 | 0.290 |
Why?
|
| Carcinoma, Ductal, Breast | 4 | 2011 | 62 | 0.290 |
Why?
|
| Models, Biological | 4 | 2013 | 981 | 0.290 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 12 | 2015 | 710 | 0.290 |
Why?
|
| Polymerase Chain Reaction | 8 | 2008 | 492 | 0.280 |
Why?
|
| South Carolina | 9 | 2015 | 2752 | 0.280 |
Why?
|
| Child Development | 1 | 2007 | 102 | 0.280 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 4 | 2014 | 137 | 0.280 |
Why?
|
| Immunotherapy | 4 | 2016 | 215 | 0.280 |
Why?
|
| Follow-Up Studies | 17 | 2016 | 3259 | 0.280 |
Why?
|
| Motor Skills Disorders | 1 | 2006 | 7 | 0.270 |
Why?
|
| Language Development Disorders | 1 | 2006 | 9 | 0.270 |
Why?
|
| Survival Analysis | 15 | 2014 | 714 | 0.270 |
Why?
|
| Chromosomes, Human | 2 | 2004 | 14 | 0.270 |
Why?
|
| Treatment Outcome | 28 | 2016 | 7029 | 0.270 |
Why?
|
| Prognosis | 14 | 2016 | 2093 | 0.270 |
Why?
|
| Lymphatic Metastasis | 8 | 2016 | 274 | 0.270 |
Why?
|
| Tobacco, Smokeless | 2 | 2016 | 40 | 0.270 |
Why?
|
| Immunotherapy, Adoptive | 3 | 2014 | 132 | 0.270 |
Why?
|
| Mice | 24 | 2016 | 8474 | 0.270 |
Why?
|
| Retrospective Studies | 25 | 2016 | 7277 | 0.260 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2016 | 79 | 0.260 |
Why?
|
| Cancer Vaccines | 3 | 2014 | 61 | 0.260 |
Why?
|
| Research Design | 8 | 2014 | 729 | 0.250 |
Why?
|
| Neoplasm Proteins | 4 | 2015 | 307 | 0.250 |
Why?
|
| Adamantane | 2 | 2015 | 40 | 0.250 |
Why?
|
| Radiotherapy, Adjuvant | 7 | 2014 | 125 | 0.250 |
Why?
|
| Prospective Studies | 17 | 2011 | 3705 | 0.250 |
Why?
|
| Urinary Bladder Neoplasms | 3 | 2013 | 138 | 0.250 |
Why?
|
| Interleukin-12 | 2 | 2015 | 75 | 0.240 |
Why?
|
| Asbestosis | 1 | 2004 | 3 | 0.240 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2016 | 231 | 0.240 |
Why?
|
| Hepatitis C | 2 | 2016 | 114 | 0.240 |
Why?
|
| Pyridines | 3 | 2015 | 261 | 0.240 |
Why?
|
| Psychotropic Drugs | 2 | 2015 | 83 | 0.240 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 3 | 2013 | 300 | 0.240 |
Why?
|
| Expert Testimony | 1 | 2004 | 47 | 0.240 |
Why?
|
| Transcription Factors | 6 | 2015 | 753 | 0.240 |
Why?
|
| Smokers | 2 | 2016 | 200 | 0.230 |
Why?
|
| Liver Neoplasms | 3 | 2016 | 334 | 0.230 |
Why?
|
| Animals | 30 | 2016 | 20881 | 0.230 |
Why?
|
| Tumor Virus Infections | 1 | 2004 | 32 | 0.230 |
Why?
|
| Deoxycytidine | 3 | 2014 | 83 | 0.230 |
Why?
|
| ErbB Receptors | 4 | 2014 | 239 | 0.230 |
Why?
|
| Phenotype | 6 | 2013 | 947 | 0.230 |
Why?
|
| Hypopigmentation | 2 | 2014 | 12 | 0.230 |
Why?
|
| Vitiligo | 2 | 2014 | 12 | 0.230 |
Why?
|
| Remission Induction | 5 | 2011 | 111 | 0.230 |
Why?
|
| Mouth Diseases | 1 | 2004 | 39 | 0.230 |
Why?
|
| RNA, Messenger | 8 | 2015 | 1664 | 0.230 |
Why?
|
| Combined Modality Therapy | 12 | 2014 | 951 | 0.220 |
Why?
|
| Risk Factors | 20 | 2014 | 5731 | 0.220 |
Why?
|
| Etoposide | 4 | 2011 | 64 | 0.220 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 2 | 2015 | 201 | 0.220 |
Why?
|
| Papillomaviridae | 1 | 2004 | 104 | 0.220 |
Why?
|
| Child Development Disorders, Pervasive | 2 | 2014 | 26 | 0.220 |
Why?
|
| Radiology | 1 | 2004 | 97 | 0.220 |
Why?
|
| Vital Statistics | 1 | 2003 | 2 | 0.220 |
Why?
|
| Birth Intervals | 1 | 2003 | 4 | 0.220 |
Why?
|
| Adoptive Transfer | 3 | 2016 | 100 | 0.220 |
Why?
|
| Loss of Heterozygosity | 1 | 2002 | 25 | 0.210 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2002 | 18 | 0.210 |
Why?
|
| Infant Mortality | 1 | 2003 | 59 | 0.210 |
Why?
|
| Chromosome Fragility | 1 | 2002 | 10 | 0.210 |
Why?
|
| Graft vs Host Disease | 3 | 2012 | 163 | 0.210 |
Why?
|
| Proportional Hazards Models | 9 | 2014 | 792 | 0.210 |
Why?
|
| Logistic Models | 15 | 2011 | 1420 | 0.210 |
Why?
|
| Uterine Neoplasms | 2 | 2016 | 99 | 0.210 |
Why?
|
| Anticarcinogenic Agents | 2 | 2016 | 52 | 0.210 |
Why?
|
| Sphingosine | 2 | 2015 | 315 | 0.200 |
Why?
|
| Mice, Transgenic | 8 | 2016 | 1033 | 0.200 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2002 | 51 | 0.200 |
Why?
|
| Autoimmunity | 2 | 2013 | 118 | 0.200 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 3 | 2010 | 33 | 0.200 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2016 | 163 | 0.200 |
Why?
|
| Multivariate Analysis | 11 | 2014 | 1046 | 0.200 |
Why?
|
| Esophageal Neoplasms | 2 | 2014 | 150 | 0.190 |
Why?
|
| Ceramides | 3 | 2015 | 578 | 0.190 |
Why?
|
| Kaplan-Meier Estimate | 7 | 2014 | 536 | 0.190 |
Why?
|
| Tumor Suppressor Proteins | 4 | 2014 | 194 | 0.190 |
Why?
|
| Quality of Health Care | 3 | 2015 | 322 | 0.190 |
Why?
|
| Papillomavirus Infections | 1 | 2004 | 194 | 0.190 |
Why?
|
| Data Collection | 2 | 2015 | 420 | 0.190 |
Why?
|
| Epitopes, T-Lymphocyte | 2 | 2016 | 38 | 0.190 |
Why?
|
| Diagnosis | 1 | 2000 | 15 | 0.190 |
Why?
|
| Marfan Syndrome | 4 | 2002 | 42 | 0.190 |
Why?
|
| Cross-Sectional Studies | 11 | 2016 | 2279 | 0.190 |
Why?
|
| Receptor, ErbB-2 | 3 | 2014 | 129 | 0.190 |
Why?
|
| Disease | 1 | 2000 | 41 | 0.190 |
Why?
|
| Mice, Inbred C57BL | 9 | 2016 | 2791 | 0.190 |
Why?
|
| Lung | 2 | 2010 | 849 | 0.180 |
Why?
|
| Epidemiologic Methods | 1 | 2000 | 83 | 0.180 |
Why?
|
| Surveys and Questionnaires | 8 | 2016 | 2800 | 0.180 |
Why?
|
| Smoking Cessation | 4 | 2016 | 1034 | 0.180 |
Why?
|
| Radiotherapy Dosage | 5 | 2014 | 125 | 0.180 |
Why?
|
| Tumor Cells, Cultured | 8 | 2015 | 852 | 0.180 |
Why?
|
| T-Lymphocytes | 3 | 2016 | 597 | 0.180 |
Why?
|
| Promoter Regions, Genetic | 8 | 2016 | 615 | 0.180 |
Why?
|
| Fluorouracil | 4 | 2015 | 130 | 0.180 |
Why?
|
| Body Mass Index | 5 | 2012 | 867 | 0.180 |
Why?
|
| Motivation | 4 | 2016 | 561 | 0.180 |
Why?
|
| DNA, Neoplasm | 6 | 2008 | 95 | 0.180 |
Why?
|
| Neoplasm Invasiveness | 7 | 2016 | 369 | 0.170 |
Why?
|
| Sirolimus | 2 | 2012 | 118 | 0.170 |
Why?
|
| Infant | 8 | 2012 | 2891 | 0.170 |
Why?
|
| Antineoplastic Agents, Hormonal | 3 | 2009 | 99 | 0.170 |
Why?
|
| Breast | 4 | 2011 | 137 | 0.170 |
Why?
|
| Colorectal Neoplasms | 5 | 2011 | 561 | 0.170 |
Why?
|
| United States | 16 | 2016 | 7367 | 0.170 |
Why?
|
| Myeloid Cells | 2 | 2011 | 57 | 0.170 |
Why?
|
| Stem Cell Transplantation | 2 | 2012 | 58 | 0.170 |
Why?
|
| Cyclophosphamide | 5 | 2014 | 129 | 0.170 |
Why?
|
| Pyrimidines | 2 | 2011 | 178 | 0.170 |
Why?
|
| Drug Administration Schedule | 9 | 2014 | 567 | 0.160 |
Why?
|
| Bone Neoplasms | 3 | 2009 | 100 | 0.160 |
Why?
|
| Piperazines | 2 | 2011 | 206 | 0.160 |
Why?
|
| Neoplasms, Experimental | 2 | 2012 | 118 | 0.160 |
Why?
|
| Odds Ratio | 9 | 2011 | 880 | 0.160 |
Why?
|
| beta 2-Microglobulin | 2 | 2008 | 15 | 0.160 |
Why?
|
| Interleukin-2 | 3 | 2015 | 133 | 0.160 |
Why?
|
| Sensitivity and Specificity | 11 | 2009 | 1753 | 0.160 |
Why?
|
| Receptors, Estrogen | 3 | 2009 | 142 | 0.160 |
Why?
|
| Mice, Knockout | 6 | 2016 | 1692 | 0.150 |
Why?
|
| Health Services Needs and Demand | 2 | 2009 | 149 | 0.150 |
Why?
|
| Nuclear Proteins | 3 | 2011 | 271 | 0.150 |
Why?
|
| Bayes Theorem | 2 | 2010 | 307 | 0.150 |
Why?
|
| Bone Marrow Transplantation | 3 | 2008 | 149 | 0.150 |
Why?
|
| Social Support | 3 | 2009 | 423 | 0.150 |
Why?
|
| Health Status Disparities | 2 | 2012 | 326 | 0.150 |
Why?
|
| Flow Cytometry | 5 | 2016 | 489 | 0.150 |
Why?
|
| Attitude to Health | 4 | 2011 | 403 | 0.140 |
Why?
|
| Cell Proliferation | 7 | 2015 | 1174 | 0.140 |
Why?
|
| Homeodomain Proteins | 2 | 2010 | 157 | 0.140 |
Why?
|
| Adolescent | 16 | 2014 | 8912 | 0.140 |
Why?
|
| Body Fluids | 2 | 2008 | 41 | 0.140 |
Why?
|
| Age Factors | 9 | 2010 | 1864 | 0.140 |
Why?
|
| Apoptosis | 6 | 2015 | 1641 | 0.140 |
Why?
|
| Proto-Oncogene Proteins c-myc | 2 | 2014 | 90 | 0.140 |
Why?
|
| Membrane Proteins | 3 | 2015 | 617 | 0.140 |
Why?
|
| Parathyroid Neoplasms | 2 | 2007 | 13 | 0.140 |
Why?
|
| Tamoxifen | 2 | 2007 | 62 | 0.140 |
Why?
|
| Child, Preschool | 7 | 2012 | 3187 | 0.140 |
Why?
|
| Mammary Glands, Human | 2 | 2007 | 33 | 0.140 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2015 | 77 | 0.140 |
Why?
|
| Retinoid X Receptor alpha | 1 | 2016 | 18 | 0.140 |
Why?
|
| Oncogene Proteins | 1 | 2016 | 35 | 0.140 |
Why?
|
| Women's Health | 4 | 2008 | 148 | 0.140 |
Why?
|
| Catechin | 1 | 2016 | 26 | 0.140 |
Why?
|
| Severity of Illness Index | 10 | 2012 | 1851 | 0.140 |
Why?
|
| Technetium Tc 99m Sestamibi | 2 | 2007 | 24 | 0.140 |
Why?
|
| Baltimore | 4 | 2004 | 34 | 0.140 |
Why?
|
| Genes, T-Cell Receptor | 1 | 2016 | 3 | 0.140 |
Why?
|
| Bacterial Toxins | 2 | 2007 | 50 | 0.130 |
Why?
|
| Parathyroid Glands | 2 | 2007 | 22 | 0.130 |
Why?
|
| Socioeconomic Factors | 3 | 2012 | 955 | 0.130 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2016 | 111 | 0.130 |
Why?
|
| Immunosuppressive Agents | 2 | 2012 | 514 | 0.130 |
Why?
|
| Antibiotics, Antineoplastic | 2 | 2008 | 82 | 0.130 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2016 | 24 | 0.130 |
Why?
|
| Spine | 2 | 2009 | 46 | 0.130 |
Why?
|
| Small Molecule Libraries | 1 | 2016 | 53 | 0.130 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2015 | 32 | 0.130 |
Why?
|
| Interleukin-12 Subunit p35 | 1 | 2015 | 6 | 0.130 |
Why?
|
| Genomic Instability | 1 | 2016 | 41 | 0.130 |
Why?
|
| Estrogen Receptor alpha | 2 | 2007 | 65 | 0.130 |
Why?
|
| Receptors, Interleukin-7 | 1 | 2015 | 9 | 0.130 |
Why?
|
| Clinical Trials as Topic | 3 | 2014 | 848 | 0.130 |
Why?
|
| Moloney murine leukemia virus | 1 | 2015 | 13 | 0.130 |
Why?
|
| Liver | 2 | 2013 | 1118 | 0.130 |
Why?
|
| Interleukin-7 | 1 | 2015 | 18 | 0.130 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 2 | 2015 | 189 | 0.130 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2015 | 331 | 0.130 |
Why?
|
| Patient Selection | 2 | 2010 | 592 | 0.130 |
Why?
|
| Longitudinal Studies | 6 | 2016 | 1054 | 0.130 |
Why?
|
| Aorta, Abdominal | 3 | 2001 | 97 | 0.130 |
Why?
|
| Transduction, Genetic | 1 | 2015 | 81 | 0.130 |
Why?
|
| Carcinoma, Lewis Lung | 1 | 2015 | 20 | 0.130 |
Why?
|
| Hepacivirus | 1 | 2016 | 90 | 0.130 |
Why?
|
| Drug Resistance, Neoplasm | 4 | 2012 | 332 | 0.130 |
Why?
|
| Adenoma | 2 | 2007 | 132 | 0.130 |
Why?
|
| Nitriles | 2 | 2014 | 68 | 0.130 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 1 | 2015 | 33 | 0.130 |
Why?
|
| Oxidoreductases | 1 | 2015 | 117 | 0.130 |
Why?
|
| Polypharmacy | 1 | 2015 | 31 | 0.130 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 5 | 2008 | 320 | 0.130 |
Why?
|
| Training Support | 1 | 2015 | 17 | 0.120 |
Why?
|
| Depression | 1 | 2002 | 943 | 0.120 |
Why?
|
| Epithelial-Mesenchymal Transition | 2 | 2013 | 135 | 0.120 |
Why?
|
| Science | 1 | 2015 | 15 | 0.120 |
Why?
|
| Salvage Therapy | 3 | 2010 | 82 | 0.120 |
Why?
|
| Salaries and Fringe Benefits | 1 | 2015 | 29 | 0.120 |
Why?
|
| Prostatectomy | 4 | 2008 | 87 | 0.120 |
Why?
|
| Molecular Docking Simulation | 1 | 2015 | 78 | 0.120 |
Why?
|
| Data Interpretation, Statistical | 2 | 2014 | 329 | 0.120 |
Why?
|
| EGF Family of Proteins | 1 | 2014 | 17 | 0.120 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2014 | 19 | 0.120 |
Why?
|
| Apolipoproteins | 2 | 2005 | 51 | 0.120 |
Why?
|
| Carcinoma, Ductal | 3 | 2010 | 14 | 0.120 |
Why?
|
| Enzyme Inhibitors | 3 | 2014 | 659 | 0.120 |
Why?
|
| Receptors, Thromboxane A2, Prostaglandin H2 | 1 | 2014 | 48 | 0.120 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2015 | 140 | 0.120 |
Why?
|
| Child Behavior Disorders | 1 | 2015 | 69 | 0.120 |
Why?
|
| Telomerase | 1 | 2015 | 85 | 0.120 |
Why?
|
| Histone Acetyltransferases | 1 | 2014 | 13 | 0.120 |
Why?
|
| Urologic Neoplasms | 1 | 2014 | 14 | 0.120 |
Why?
|
| Antibodies, Monoclonal | 2 | 2010 | 511 | 0.120 |
Why?
|
| Sphingosine N-Acyltransferase | 1 | 2015 | 62 | 0.120 |
Why?
|
| Pigmentation | 1 | 2014 | 12 | 0.120 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 2005 | 88 | 0.120 |
Why?
|
| Esophagectomy | 1 | 2014 | 26 | 0.120 |
Why?
|
| Protein Phosphatase 2 | 2 | 2012 | 67 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2014 | 54 | 0.120 |
Why?
|
| Incidence | 5 | 2010 | 1603 | 0.120 |
Why?
|
| Epidermis | 1 | 2014 | 42 | 0.120 |
Why?
|
| Acid Ceramidase | 1 | 2015 | 85 | 0.120 |
Why?
|
| Wnt Signaling Pathway | 1 | 2014 | 57 | 0.120 |
Why?
|
| Sulfhydryl Compounds | 1 | 2014 | 73 | 0.120 |
Why?
|
| Forkhead Transcription Factors | 1 | 2014 | 94 | 0.120 |
Why?
|
| Immunity | 1 | 2014 | 67 | 0.120 |
Why?
|
| Cell Nucleus | 1 | 2015 | 305 | 0.120 |
Why?
|
| Faculty, Medical | 1 | 2015 | 110 | 0.120 |
Why?
|
| Thoracic Wall | 1 | 2014 | 20 | 0.120 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2014 | 30 | 0.120 |
Why?
|
| Oncogenes | 1 | 2014 | 71 | 0.120 |
Why?
|
| Xenograft Model Antitumor Assays | 5 | 2015 | 304 | 0.120 |
Why?
|
| Child | 13 | 2015 | 6405 | 0.110 |
Why?
|
| Chemoradiotherapy | 1 | 2014 | 54 | 0.110 |
Why?
|
| Lysophospholipids | 1 | 2015 | 209 | 0.110 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2014 | 108 | 0.110 |
Why?
|
| Induction Chemotherapy | 1 | 2014 | 39 | 0.110 |
Why?
|
| Epigenesis, Genetic | 2 | 2006 | 163 | 0.110 |
Why?
|
| Cadherins | 3 | 2010 | 93 | 0.110 |
Why?
|
| Neuropilin-2 | 1 | 2013 | 19 | 0.110 |
Why?
|
| Universities | 1 | 2015 | 191 | 0.110 |
Why?
|
| Multiple Myeloma | 1 | 2014 | 92 | 0.110 |
Why?
|
| Ablation Techniques | 1 | 2013 | 33 | 0.110 |
Why?
|
| Aminoglycosides | 1 | 2013 | 54 | 0.110 |
Why?
|
| Phosphorylation | 5 | 2015 | 1200 | 0.110 |
Why?
|
| Small Cell Lung Carcinoma | 2 | 2010 | 17 | 0.110 |
Why?
|
| Educational Status | 3 | 2010 | 273 | 0.110 |
Why?
|
| Intensive Care Units | 5 | 2004 | 344 | 0.110 |
Why?
|
| Cohort Studies | 9 | 2014 | 2358 | 0.110 |
Why?
|
| Autism Spectrum Disorder | 1 | 2015 | 111 | 0.110 |
Why?
|
| Adenoviridae | 1 | 2013 | 295 | 0.110 |
Why?
|
| Medical Oncology | 1 | 2014 | 110 | 0.110 |
Why?
|
| Lymphocyte Depletion | 2 | 2015 | 34 | 0.110 |
Why?
|
| Mutant Proteins | 1 | 2013 | 45 | 0.110 |
Why?
|
| Histone Chaperones | 1 | 2012 | 11 | 0.110 |
Why?
|
| Gene Transfer Techniques | 1 | 2013 | 173 | 0.110 |
Why?
|
| Propylene Glycols | 1 | 2012 | 16 | 0.110 |
Why?
|
| Academic Medical Centers | 1 | 2015 | 281 | 0.110 |
Why?
|
| Movement | 1 | 2014 | 179 | 0.110 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2013 | 126 | 0.110 |
Why?
|
| Physicians | 2 | 2007 | 324 | 0.110 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2013 | 42 | 0.110 |
Why?
|
| Receptor-Interacting Protein Serine-Threonine Kinases | 1 | 2012 | 30 | 0.110 |
Why?
|
| Students | 1 | 2015 | 233 | 0.110 |
Why?
|
| Young Adult | 6 | 2014 | 5717 | 0.110 |
Why?
|
| Antigens, CD | 2 | 2011 | 230 | 0.110 |
Why?
|
| Cell Line | 6 | 2016 | 1752 | 0.110 |
Why?
|
| Brachytherapy | 2 | 2010 | 79 | 0.110 |
Why?
|
| Lumbar Vertebrae | 3 | 2002 | 112 | 0.100 |
Why?
|
| Hospital Mortality | 4 | 2003 | 384 | 0.100 |
Why?
|
| Equipment Design | 1 | 2014 | 500 | 0.100 |
Why?
|
| Folic Acid Antagonists | 1 | 2012 | 20 | 0.100 |
Why?
|
| Transplantation, Autologous | 3 | 2007 | 145 | 0.100 |
Why?
|
| Vitamin B Complex | 1 | 2012 | 26 | 0.100 |
Why?
|
| Leucovorin | 1 | 2012 | 35 | 0.100 |
Why?
|
| Receptors, CXCR4 | 1 | 2012 | 48 | 0.100 |
Why?
|
| Transcription, Genetic | 3 | 2014 | 562 | 0.100 |
Why?
|
| Temperature | 1 | 2013 | 341 | 0.100 |
Why?
|
| Patient Satisfaction | 1 | 2015 | 378 | 0.100 |
Why?
|
| Chemokine CXCL12 | 1 | 2012 | 51 | 0.100 |
Why?
|
| Watchful Waiting | 1 | 2012 | 25 | 0.100 |
Why?
|
| Radiotherapy | 2 | 2010 | 86 | 0.100 |
Why?
|
| Models, Genetic | 2 | 2010 | 161 | 0.100 |
Why?
|
| Neoplasm Metastasis | 5 | 2014 | 306 | 0.100 |
Why?
|
| Disability Evaluation | 4 | 2003 | 298 | 0.100 |
Why?
|
| Self Efficacy | 2 | 2010 | 199 | 0.100 |
Why?
|
| Cytochrome P-450 CYP3A | 2 | 2011 | 22 | 0.100 |
Why?
|
| Cisplatin | 5 | 2010 | 192 | 0.100 |
Why?
|
| Dog Diseases | 1 | 2012 | 45 | 0.100 |
Why?
|
| Methotrexate | 1 | 2012 | 91 | 0.100 |
Why?
|
| Lymphocyte Activation | 4 | 2015 | 397 | 0.100 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 2011 | 19 | 0.100 |
Why?
|
| Time Factors | 8 | 2016 | 4655 | 0.100 |
Why?
|
| Polymers | 1 | 2013 | 244 | 0.100 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2012 | 126 | 0.100 |
Why?
|
| Radiation Injuries | 2 | 2010 | 97 | 0.100 |
Why?
|
| Nursing Staff, Hospital | 2 | 2003 | 62 | 0.100 |
Why?
|
| Lymphoma | 1 | 2012 | 116 | 0.100 |
Why?
|
| Health Surveys | 3 | 2011 | 489 | 0.100 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2012 | 118 | 0.100 |
Why?
|
| Nomograms | 2 | 2009 | 19 | 0.100 |
Why?
|
| Mice, Nude | 5 | 2013 | 294 | 0.100 |
Why?
|
| Mice, SCID | 4 | 2015 | 238 | 0.100 |
Why?
|
| Triazoles | 1 | 2011 | 43 | 0.100 |
Why?
|
| Gonadotropin-Releasing Hormone | 1 | 2011 | 32 | 0.100 |
Why?
|
| Boronic Acids | 1 | 2011 | 40 | 0.100 |
Why?
|
| Biomedical Research | 1 | 2015 | 310 | 0.100 |
Why?
|
| Receptor, EphA2 | 1 | 2011 | 3 | 0.100 |
Why?
|
| Prostate | 1 | 2012 | 116 | 0.100 |
Why?
|
| Low Density Lipoprotein Receptor-Related Protein-1 | 1 | 2011 | 9 | 0.100 |
Why?
|
| Pyrazines | 1 | 2011 | 46 | 0.100 |
Why?
|
| Polyradiculopathy | 2 | 2001 | 6 | 0.100 |
Why?
|
| Medication Adherence | 1 | 2014 | 335 | 0.100 |
Why?
|
| Case-Control Studies | 4 | 2010 | 1553 | 0.100 |
Why?
|
| Cyclosporine | 2 | 2012 | 121 | 0.090 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2016 | 209 | 0.090 |
Why?
|
| Erythrocyte Transfusion | 2 | 2009 | 72 | 0.090 |
Why?
|
| Cysteine Proteinase Inhibitors | 1 | 2011 | 73 | 0.090 |
Why?
|
| Myelodysplastic Syndromes | 2 | 2008 | 24 | 0.090 |
Why?
|
| Genetic Therapy | 1 | 2013 | 291 | 0.090 |
Why?
|
| DNA-Binding Proteins | 2 | 2012 | 700 | 0.090 |
Why?
|
| Erythropoietin | 2 | 2001 | 96 | 0.090 |
Why?
|
| Blood Transfusion, Autologous | 2 | 2009 | 17 | 0.090 |
Why?
|
| Prescription Drugs | 1 | 2012 | 71 | 0.090 |
Why?
|
| Dura Mater | 2 | 2001 | 23 | 0.090 |
Why?
|
| Indium Radioisotopes | 1 | 2010 | 19 | 0.090 |
Why?
|
| Immune Tolerance | 1 | 2011 | 114 | 0.090 |
Why?
|
| Decision Making | 4 | 2007 | 410 | 0.090 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2011 | 46 | 0.090 |
Why?
|
| Delivery of Health Care | 1 | 2015 | 445 | 0.090 |
Why?
|
| Farnesyltranstransferase | 2 | 2008 | 5 | 0.090 |
Why?
|
| Receptors, Progesterone | 3 | 2007 | 57 | 0.090 |
Why?
|
| Maryland | 7 | 2007 | 77 | 0.090 |
Why?
|
| Linear Models | 7 | 2009 | 521 | 0.090 |
Why?
|
| Skin Neoplasms | 1 | 2015 | 375 | 0.090 |
Why?
|
| Carcinoma, Small Cell | 1 | 2010 | 53 | 0.090 |
Why?
|
| Cryosurgery | 1 | 2010 | 53 | 0.090 |
Why?
|
| Fruit | 2 | 2008 | 86 | 0.090 |
Why?
|
| Vegetables | 2 | 2008 | 76 | 0.090 |
Why?
|
| Anemia | 2 | 2001 | 104 | 0.090 |
Why?
|
| Vitamin A | 2 | 2001 | 111 | 0.090 |
Why?
|
| Probability | 5 | 2014 | 245 | 0.090 |
Why?
|
| Carcinoma | 1 | 2012 | 215 | 0.090 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2012 | 148 | 0.090 |
Why?
|
| Transplantation, Homologous | 5 | 2012 | 242 | 0.090 |
Why?
|
| Estrogens | 1 | 2011 | 173 | 0.090 |
Why?
|
| Communication | 2 | 2010 | 329 | 0.090 |
Why?
|
| Pharmacy and Therapeutics Committee | 1 | 2010 | 7 | 0.090 |
Why?
|
| Self-Assessment | 1 | 2010 | 69 | 0.090 |
Why?
|
| Drugs, Investigational | 1 | 2010 | 18 | 0.090 |
Why?
|
| Linezolid | 1 | 2010 | 7 | 0.090 |
Why?
|
| Oxazolidinones | 1 | 2010 | 6 | 0.090 |
Why?
|
| Daptomycin | 1 | 2010 | 11 | 0.090 |
Why?
|
| Acetamides | 1 | 2010 | 17 | 0.090 |
Why?
|
| Neoplasm, Residual | 1 | 2010 | 33 | 0.090 |
Why?
|
| Ciprofloxacin | 1 | 2010 | 30 | 0.090 |
Why?
|
| Enterococcus | 1 | 2010 | 29 | 0.090 |
Why?
|
| Aminocaproic Acid | 1 | 2009 | 12 | 0.090 |
Why?
|
| Predictive Value of Tests | 4 | 2011 | 1465 | 0.090 |
Why?
|
| Hemostasis, Surgical | 1 | 2009 | 18 | 0.090 |
Why?
|
| Vancomycin | 1 | 2010 | 60 | 0.090 |
Why?
|
| Consensus | 1 | 2010 | 211 | 0.090 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2010 | 63 | 0.090 |
Why?
|
| Carboplatin | 4 | 2010 | 59 | 0.090 |
Why?
|
| Health Services Accessibility | 3 | 2009 | 581 | 0.080 |
Why?
|
| Mammary Glands, Animal | 2 | 2007 | 71 | 0.080 |
Why?
|
| Organophosphorus Compounds | 1 | 2009 | 13 | 0.080 |
Why?
|
| Heart Ventricles | 1 | 2014 | 738 | 0.080 |
Why?
|
| Algorithms | 4 | 2014 | 1196 | 0.080 |
Why?
|
| Tobacco Use Disorder | 1 | 2014 | 432 | 0.080 |
Why?
|
| Schizophrenic Psychology | 1 | 2009 | 53 | 0.080 |
Why?
|
| Mitoxantrone | 4 | 2012 | 7 | 0.080 |
Why?
|
| RNA Interference | 3 | 2016 | 266 | 0.080 |
Why?
|
| Social Behavior | 2 | 2007 | 164 | 0.080 |
Why?
|
| Osteotomy | 1 | 2009 | 46 | 0.080 |
Why?
|
| Postoperative Hemorrhage | 1 | 2009 | 69 | 0.080 |
Why?
|
| Osteosarcoma | 1 | 2009 | 35 | 0.080 |
Why?
|
| Antifibrinolytic Agents | 1 | 2009 | 52 | 0.080 |
Why?
|
| Coercion | 1 | 2009 | 11 | 0.080 |
Why?
|
| DNA Primers | 5 | 2008 | 302 | 0.080 |
Why?
|
| Chemotherapy, Adjuvant | 4 | 2011 | 129 | 0.080 |
Why?
|
| Physician Assistants | 2 | 2006 | 47 | 0.080 |
Why?
|
| Blood Loss, Surgical | 1 | 2009 | 79 | 0.080 |
Why?
|
| Dacarbazine | 1 | 2009 | 32 | 0.080 |
Why?
|
| Vascular Surgical Procedures | 2 | 2001 | 168 | 0.080 |
Why?
|
| Diphtheria Toxin | 1 | 2008 | 18 | 0.080 |
Why?
|
| Prednisone | 4 | 2012 | 104 | 0.080 |
Why?
|
| Nurse Practitioners | 2 | 2006 | 90 | 0.080 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 2 | 2006 | 10 | 0.080 |
Why?
|
| Esophagitis | 1 | 2008 | 45 | 0.080 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2009 | 57 | 0.080 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 2 | 2016 | 100 | 0.080 |
Why?
|
| Catheterization | 1 | 2009 | 209 | 0.080 |
Why?
|
| Postmenopause | 2 | 2011 | 93 | 0.080 |
Why?
|
| Parathyroidectomy | 2 | 2005 | 45 | 0.080 |
Why?
|
| Spinal Fusion | 1 | 2009 | 90 | 0.080 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2007 | 195 | 0.080 |
Why?
|
| Educational Measurement | 1 | 2010 | 254 | 0.080 |
Why?
|
| Organometallic Compounds | 1 | 2009 | 95 | 0.080 |
Why?
|
| Azacitidine | 2 | 2006 | 20 | 0.080 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2012 | 767 | 0.080 |
Why?
|
| Apolipoproteins C | 2 | 2005 | 15 | 0.080 |
Why?
|
| Keratin-19 | 1 | 2008 | 2 | 0.080 |
Why?
|
| SEER Program | 3 | 2014 | 153 | 0.080 |
Why?
|
| Physician-Patient Relations | 1 | 2010 | 261 | 0.080 |
Why?
|
| Glioblastoma | 1 | 2011 | 219 | 0.080 |
Why?
|
| Radiopharmaceuticals | 2 | 2007 | 114 | 0.080 |
Why?
|
| Body Size | 1 | 2008 | 39 | 0.080 |
Why?
|
| Length of Stay | 7 | 2009 | 780 | 0.080 |
Why?
|
| Laryngeal Neoplasms | 1 | 2008 | 47 | 0.080 |
Why?
|
| Critical Care | 3 | 2009 | 263 | 0.080 |
Why?
|
| Regression Analysis | 6 | 2007 | 737 | 0.080 |
Why?
|
| Vinblastine | 1 | 2007 | 40 | 0.080 |
Why?
|
| Topotecan | 1 | 2007 | 17 | 0.080 |
Why?
|
| Receptors, Thromboxane | 1 | 2008 | 122 | 0.080 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2008 | 2223 | 0.080 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2008 | 114 | 0.080 |
Why?
|
| Disease Models, Animal | 4 | 2016 | 2550 | 0.080 |
Why?
|
| Developing Countries | 1 | 2009 | 106 | 0.080 |
Why?
|
| Validation Studies as Topic | 1 | 2007 | 7 | 0.080 |
Why?
|
| Graft vs Tumor Effect | 1 | 2007 | 2 | 0.080 |
Why?
|
| Calmodulin | 1 | 2008 | 53 | 0.070 |
Why?
|
| Lipoproteins, HDL | 2 | 2005 | 113 | 0.070 |
Why?
|
| Solitary Pulmonary Nodule | 1 | 2009 | 77 | 0.070 |
Why?
|
| Glioma | 1 | 2009 | 140 | 0.070 |
Why?
|
| Informed Consent | 1 | 2009 | 127 | 0.070 |
Why?
|
| Hodgkin Disease | 1 | 2007 | 27 | 0.070 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2007 | 97 | 0.070 |
Why?
|
| Play and Playthings | 1 | 2007 | 22 | 0.070 |
Why?
|
| Postoperative Complications | 4 | 2003 | 1615 | 0.070 |
Why?
|
| Protein Isoforms | 1 | 2008 | 246 | 0.070 |
Why?
|
| Intraoperative Care | 1 | 2008 | 91 | 0.070 |
Why?
|
| Medicaid | 3 | 2015 | 302 | 0.070 |
Why?
|
| Language Tests | 1 | 2007 | 36 | 0.070 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2007 | 36 | 0.070 |
Why?
|
| Brain Neoplasms | 2 | 2009 | 371 | 0.070 |
Why?
|
| Leiomyosarcoma | 1 | 2007 | 17 | 0.070 |
Why?
|
| Phenylurea Compounds | 1 | 2007 | 31 | 0.070 |
Why?
|
| Thiocyanates | 1 | 2007 | 5 | 0.070 |
Why?
|
| Pore Forming Cytotoxic Proteins | 1 | 2007 | 8 | 0.070 |
Why?
|
| Third-Party Consent | 1 | 2007 | 7 | 0.070 |
Why?
|
| Sulfur | 1 | 2007 | 16 | 0.070 |
Why?
|
| Siblings | 1 | 2007 | 34 | 0.070 |
Why?
|
| Brassica | 1 | 2007 | 13 | 0.070 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2008 | 94 | 0.070 |
Why?
|
| Infant, Newborn | 5 | 2005 | 2455 | 0.070 |
Why?
|
| Receptors, Retinoic Acid | 2 | 2004 | 48 | 0.070 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2008 | 376 | 0.070 |
Why?
|
| Cyclins | 2 | 2004 | 50 | 0.070 |
Why?
|
| Ethics, Clinical | 1 | 2007 | 9 | 0.070 |
Why?
|
| Ethics Consultation | 1 | 2007 | 5 | 0.070 |
Why?
|
| Prodrugs | 2 | 2007 | 54 | 0.070 |
Why?
|
| Ultrasonography, Interventional | 1 | 2008 | 119 | 0.070 |
Why?
|
| Prostatic Hyperplasia | 1 | 2007 | 25 | 0.070 |
Why?
|
| Demography | 3 | 2016 | 279 | 0.070 |
Why?
|
| Mental Competency | 1 | 2007 | 29 | 0.070 |
Why?
|
| Microtubules | 1 | 2007 | 104 | 0.070 |
Why?
|
| tau Proteins | 1 | 2007 | 61 | 0.070 |
Why?
|
| Poverty | 1 | 2008 | 219 | 0.070 |
Why?
|
| Nutritional Physiological Phenomena | 1 | 2006 | 24 | 0.070 |
Why?
|
| Public Housing | 1 | 2006 | 12 | 0.070 |
Why?
|
| Managed Care Programs | 1 | 2006 | 45 | 0.070 |
Why?
|
| Personality Inventory | 1 | 2007 | 197 | 0.070 |
Why?
|
| Statistics, Nonparametric | 1 | 2007 | 306 | 0.070 |
Why?
|
| Adolescent Behavior | 1 | 2009 | 264 | 0.070 |
Why?
|
| Culture | 1 | 2007 | 75 | 0.070 |
Why?
|
| Diet | 2 | 2008 | 514 | 0.070 |
Why?
|
| Urban Health | 1 | 2006 | 49 | 0.070 |
Why?
|
| Lymphocyte Transfusion | 1 | 2006 | 4 | 0.070 |
Why?
|
| Graft vs Host Reaction | 1 | 2006 | 4 | 0.070 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2015 | 411 | 0.070 |
Why?
|
| Professional-Patient Relations | 1 | 2006 | 71 | 0.070 |
Why?
|
| Health Care Rationing | 1 | 2006 | 32 | 0.070 |
Why?
|
| Heterografts | 1 | 2016 | 70 | 0.070 |
Why?
|
| Parkinson Disease | 1 | 2009 | 272 | 0.070 |
Why?
|
| X-Linked Inhibitor of Apoptosis Protein | 1 | 2006 | 17 | 0.070 |
Why?
|
| Terminally Ill | 1 | 2006 | 17 | 0.070 |
Why?
|
| Observer Variation | 2 | 2004 | 330 | 0.070 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2006 | 47 | 0.070 |
Why?
|
| Estrogen Antagonists | 1 | 2006 | 10 | 0.070 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2011 | 2324 | 0.070 |
Why?
|
| Gestational Age | 2 | 2005 | 389 | 0.070 |
Why?
|
| Perioperative Care | 1 | 2007 | 100 | 0.070 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2009 | 373 | 0.070 |
Why?
|
| Feasibility Studies | 3 | 2014 | 652 | 0.070 |
Why?
|
| Immunoglobulin G | 1 | 2008 | 481 | 0.070 |
Why?
|
| Lymphoma, Follicular | 1 | 2005 | 6 | 0.070 |
Why?
|
| Signal Transduction | 5 | 2015 | 2689 | 0.070 |
Why?
|
| Hyperparathyroidism, Secondary | 1 | 2005 | 6 | 0.070 |
Why?
|
| Confidence Intervals | 3 | 2011 | 242 | 0.070 |
Why?
|
| Hypocalcemia | 1 | 2005 | 13 | 0.070 |
Why?
|
| Fetal Blood | 2 | 2005 | 131 | 0.070 |
Why?
|
| Reproducibility of Results | 6 | 2009 | 2077 | 0.070 |
Why?
|
| Hematologic Neoplasms | 1 | 2006 | 37 | 0.070 |
Why?
|
| Spores, Bacterial | 1 | 2005 | 17 | 0.070 |
Why?
|
| TRPP Cation Channels | 1 | 2005 | 20 | 0.070 |
Why?
|
| Clostridium | 1 | 2005 | 10 | 0.070 |
Why?
|
| Chi-Square Distribution | 2 | 2004 | 546 | 0.070 |
Why?
|
| Venous Thrombosis | 1 | 2007 | 125 | 0.060 |
Why?
|
| Polycystic Kidney, Autosomal Dominant | 1 | 2005 | 25 | 0.060 |
Why?
|
| Sacrum | 2 | 2002 | 14 | 0.060 |
Why?
|
| Parental Consent | 1 | 2005 | 2 | 0.060 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2006 | 44 | 0.060 |
Why?
|
| Down-Regulation | 3 | 2014 | 447 | 0.060 |
Why?
|
| Recurrence | 4 | 2011 | 948 | 0.060 |
Why?
|
| Cytokines | 3 | 2005 | 866 | 0.060 |
Why?
|
| Activities of Daily Living | 2 | 2008 | 319 | 0.060 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2005 | 44 | 0.060 |
Why?
|
| Gift Giving | 1 | 2005 | 10 | 0.060 |
Why?
|
| Disease Progression | 4 | 2013 | 1038 | 0.060 |
Why?
|
| Malaria | 1 | 2005 | 26 | 0.060 |
Why?
|
| Cooperative Behavior | 1 | 2007 | 235 | 0.060 |
Why?
|
| Histones | 1 | 2006 | 111 | 0.060 |
Why?
|
| Risk Assessment | 6 | 2010 | 2007 | 0.060 |
Why?
|
| Interleukin-15 | 2 | 2015 | 66 | 0.060 |
Why?
|
| Cells, Cultured | 4 | 2015 | 2673 | 0.060 |
Why?
|
| Protein Binding | 3 | 2015 | 1027 | 0.060 |
Why?
|
| Lymphoma, Mantle-Cell | 1 | 2005 | 9 | 0.060 |
Why?
|
| Terminal Care | 1 | 2006 | 92 | 0.060 |
Why?
|
| Placenta | 1 | 2005 | 101 | 0.060 |
Why?
|
| Sialoglycoproteins | 1 | 2004 | 24 | 0.060 |
Why?
|
| Polyethylene Glycols | 1 | 2006 | 149 | 0.060 |
Why?
|
| Antimalarials | 1 | 2005 | 71 | 0.060 |
Why?
|
| Infant, Small for Gestational Age | 1 | 2005 | 46 | 0.060 |
Why?
|
| Lymphokines | 1 | 2004 | 49 | 0.060 |
Why?
|
| Sulfites | 1 | 2004 | 7 | 0.060 |
Why?
|
| Infant, Low Birth Weight | 1 | 2005 | 84 | 0.060 |
Why?
|
| Attention | 1 | 2007 | 225 | 0.060 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2007 | 782 | 0.060 |
Why?
|
| Uganda | 4 | 2009 | 41 | 0.060 |
Why?
|
| Base Sequence | 4 | 2008 | 1015 | 0.060 |
Why?
|
| Hemoglobinuria, Paroxysmal | 1 | 2004 | 2 | 0.060 |
Why?
|
| Hyperparathyroidism | 1 | 2004 | 40 | 0.060 |
Why?
|
| Feeding Behavior | 1 | 2006 | 224 | 0.060 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 2004 | 67 | 0.060 |
Why?
|
| Pleura | 1 | 2004 | 25 | 0.060 |
Why?
|
| Consultants | 1 | 2004 | 12 | 0.060 |
Why?
|
| Blotting, Western | 3 | 2015 | 954 | 0.060 |
Why?
|
| HLA-A2 Antigen | 2 | 2016 | 18 | 0.060 |
Why?
|
| Forensic Medicine | 1 | 2004 | 26 | 0.060 |
Why?
|
| CpG Islands | 1 | 2004 | 51 | 0.060 |
Why?
|
| Tumor Burden | 3 | 2010 | 132 | 0.060 |
Why?
|
| Genes, BRCA1 | 1 | 2004 | 47 | 0.060 |
Why?
|
| Cell Movement | 3 | 2014 | 630 | 0.060 |
Why?
|
| Catheters, Indwelling | 1 | 2004 | 72 | 0.060 |
Why?
|
| RNA, Neoplasm | 3 | 2014 | 76 | 0.060 |
Why?
|
| Calcium Channel Blockers | 1 | 2004 | 138 | 0.060 |
Why?
|
| Rectocele | 1 | 2004 | 2 | 0.060 |
Why?
|
| ROC Curve | 4 | 2008 | 392 | 0.060 |
Why?
|
| HIV Seronegativity | 1 | 2004 | 11 | 0.060 |
Why?
|
| Seroepidemiologic Studies | 1 | 2004 | 41 | 0.060 |
Why?
|
| Health Benefit Plans, Employee | 1 | 2004 | 7 | 0.060 |
Why?
|
| Living Donors | 1 | 2006 | 160 | 0.060 |
Why?
|
| Urinary Bladder Diseases | 1 | 2004 | 26 | 0.060 |
Why?
|
| Family | 1 | 2006 | 293 | 0.060 |
Why?
|
| Capecitabine | 2 | 2014 | 11 | 0.060 |
Why?
|
| Pain | 1 | 2007 | 472 | 0.060 |
Why?
|
| Risk | 3 | 2012 | 563 | 0.060 |
Why?
|
| Radiography, Thoracic | 1 | 2004 | 99 | 0.060 |
Why?
|
| Uterine Prolapse | 1 | 2004 | 29 | 0.060 |
Why?
|
| Pilot Projects | 4 | 2010 | 1342 | 0.060 |
Why?
|
| Catheterization, Central Venous | 1 | 2004 | 89 | 0.060 |
Why?
|
| Phosphoproteins | 1 | 2005 | 202 | 0.060 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2007 | 786 | 0.060 |
Why?
|
| Phylogeny | 1 | 2004 | 197 | 0.060 |
Why?
|
| DNA, Viral | 1 | 2004 | 114 | 0.060 |
Why?
|
| Thapsigargin | 1 | 2003 | 18 | 0.060 |
Why?
|
| HIV Seropositivity | 1 | 2004 | 66 | 0.060 |
Why?
|
| Consumer Behavior | 1 | 2004 | 68 | 0.060 |
Why?
|
| Pneumonia, Aspiration | 1 | 2003 | 22 | 0.060 |
Why?
|
| T-Lymphocytes, Regulatory | 2 | 2015 | 199 | 0.060 |
Why?
|
| Health Resources | 1 | 2004 | 76 | 0.060 |
Why?
|
| Paclitaxel | 3 | 2010 | 140 | 0.060 |
Why?
|
| Triglycerides | 1 | 2004 | 184 | 0.060 |
Why?
|
| Tight Junctions | 1 | 2003 | 25 | 0.060 |
Why?
|
| Noise, Occupational | 1 | 2003 | 1 | 0.050 |
Why?
|
| Scotland | 1 | 2003 | 18 | 0.050 |
Why?
|
| Health Facility Environment | 1 | 2003 | 11 | 0.050 |
Why?
|
| Acute Disease | 4 | 2008 | 658 | 0.050 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2006 | 626 | 0.050 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2002 | 240 | 0.050 |
Why?
|
| Anti-Bacterial Agents | 1 | 2010 | 1026 | 0.050 |
Why?
|
| England | 1 | 2003 | 64 | 0.050 |
Why?
|
| Gene Knockdown Techniques | 2 | 2014 | 196 | 0.050 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2002 | 95 | 0.050 |
Why?
|
| Lipoproteins | 1 | 2004 | 161 | 0.050 |
Why?
|
| Microsatellite Repeats | 1 | 2002 | 40 | 0.050 |
Why?
|
| Sequence Alignment | 1 | 2003 | 165 | 0.050 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2003 | 114 | 0.050 |
Why?
|
| Blood Component Transfusion | 1 | 2002 | 11 | 0.050 |
Why?
|
| Osteoarthritis, Knee | 1 | 2003 | 26 | 0.050 |
Why?
|
| History, 19th Century | 1 | 2003 | 95 | 0.050 |
Why?
|
| Spindle Apparatus | 1 | 2002 | 13 | 0.050 |
Why?
|
| Blood Cells | 1 | 2002 | 27 | 0.050 |
Why?
|
| Transplantation, Heterologous | 3 | 2012 | 122 | 0.050 |
Why?
|
| Sex Distribution | 2 | 2016 | 274 | 0.050 |
Why?
|
| Genetic Markers | 1 | 2002 | 144 | 0.050 |
Why?
|
| Enzyme Activation | 3 | 2011 | 791 | 0.050 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2014 | 235 | 0.050 |
Why?
|
| Erlotinib Hydrochloride | 2 | 2012 | 12 | 0.050 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2002 | 29 | 0.050 |
Why?
|
| Sulindac | 1 | 2002 | 4 | 0.050 |
Why?
|
| Transfection | 3 | 2013 | 782 | 0.050 |
Why?
|
| Caregivers | 1 | 2006 | 365 | 0.050 |
Why?
|
| Aspartic Acid | 1 | 2002 | 65 | 0.050 |
Why?
|
| Adrenoleukodystrophy | 1 | 2002 | 45 | 0.050 |
Why?
|
| Intensive Care Units, Pediatric | 1 | 2003 | 101 | 0.050 |
Why?
|
| Adenomatous Polyposis Coli | 1 | 2002 | 26 | 0.050 |
Why?
|
| Proteins | 1 | 2006 | 474 | 0.050 |
Why?
|
| Computer Simulation | 3 | 2011 | 706 | 0.050 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2014 | 151 | 0.050 |
Why?
|
| Prevalence | 5 | 2006 | 1619 | 0.050 |
Why?
|
| Mitosis | 1 | 2002 | 76 | 0.050 |
Why?
|
| Lymph Node Excision | 2 | 2014 | 91 | 0.050 |
Why?
|
| CD3 Complex | 2 | 2012 | 35 | 0.050 |
Why?
|
| Brain Chemistry | 1 | 2002 | 173 | 0.050 |
Why?
|
| Cognition Disorders | 2 | 2009 | 342 | 0.050 |
Why?
|
| Malaria, Falciparum | 1 | 2001 | 10 | 0.050 |
Why?
|
| Analysis of Variance | 3 | 2010 | 1040 | 0.050 |
Why?
|
| Quinazolines | 2 | 2012 | 70 | 0.050 |
Why?
|
| Monte Carlo Method | 1 | 2002 | 124 | 0.050 |
Why?
|
| Hyperglycemia | 1 | 2003 | 158 | 0.050 |
Why?
|
| DNA | 1 | 2004 | 597 | 0.050 |
Why?
|
| Spondylitis, Ankylosing | 1 | 2001 | 10 | 0.050 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2014 | 84 | 0.050 |
Why?
|
| Markov Chains | 1 | 2002 | 133 | 0.050 |
Why?
|
| RNA, Small Interfering | 2 | 2014 | 434 | 0.050 |
Why?
|
| Leukemia, Myeloid | 1 | 2001 | 39 | 0.050 |
Why?
|
| Sepsis | 1 | 2004 | 233 | 0.050 |
Why?
|
| Mouth Neoplasms | 1 | 2004 | 206 | 0.050 |
Why?
|
| Failure to Thrive | 1 | 2001 | 17 | 0.050 |
Why?
|
| Pregnancy Complications, Hematologic | 1 | 2001 | 15 | 0.050 |
Why?
|
| Cluster Analysis | 2 | 2014 | 219 | 0.050 |
Why?
|
| Vitamin E | 1 | 2001 | 55 | 0.050 |
Why?
|
| Up-Regulation | 3 | 2013 | 682 | 0.050 |
Why?
|
| Carotenoids | 1 | 2001 | 45 | 0.050 |
Why?
|
| Genetic Variation | 1 | 2002 | 220 | 0.050 |
Why?
|
| Granzymes | 2 | 2015 | 19 | 0.050 |
Why?
|
| Immunohistochemistry | 3 | 2011 | 1174 | 0.050 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2001 | 64 | 0.050 |
Why?
|
| Biomarkers | 4 | 2011 | 1593 | 0.050 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2002 | 346 | 0.050 |
Why?
|
| Stress, Psychological | 2 | 2009 | 824 | 0.050 |
Why?
|
| Quality of Life | 1 | 2009 | 1515 | 0.050 |
Why?
|
| Hydroxycholecalciferols | 1 | 2000 | 29 | 0.050 |
Why?
|
| Carcinoma in Situ | 1 | 2001 | 47 | 0.050 |
Why?
|
| Double-Blind Method | 4 | 2009 | 1738 | 0.050 |
Why?
|
| Interleukin-10 | 1 | 2001 | 144 | 0.050 |
Why?
|
| Mitochondria | 1 | 2006 | 643 | 0.050 |
Why?
|
| Anthropometry | 1 | 2001 | 64 | 0.050 |
Why?
|
| Pancreatic Ducts | 1 | 2001 | 76 | 0.050 |
Why?
|
| Axilla | 2 | 2010 | 36 | 0.050 |
Why?
|
| Precancerous Conditions | 1 | 2001 | 74 | 0.050 |
Why?
|
| Imatinib Mesylate | 2 | 2011 | 26 | 0.050 |
Why?
|
| Aging | 3 | 2003 | 911 | 0.050 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2002 | 268 | 0.050 |
Why?
|
| Biopsy, Needle | 2 | 2011 | 191 | 0.050 |
Why?
|
| Blood Transfusion | 1 | 2002 | 205 | 0.050 |
Why?
|
| Intervertebral Disc Displacement | 1 | 2000 | 17 | 0.040 |
Why?
|
| Blood Glucose | 1 | 2003 | 631 | 0.040 |
Why?
|
| Terminology as Topic | 1 | 2001 | 141 | 0.040 |
Why?
|
| Biometry | 1 | 2000 | 72 | 0.040 |
Why?
|
| Population Surveillance | 2 | 2012 | 285 | 0.040 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 2001 | 139 | 0.040 |
Why?
|
| Decompression, Surgical | 1 | 2000 | 55 | 0.040 |
Why?
|
| Mastectomy, Segmental | 2 | 2010 | 64 | 0.040 |
Why?
|
| Geriatric Assessment | 1 | 2000 | 107 | 0.040 |
Why?
|
| Neoplasm Transplantation | 2 | 2012 | 160 | 0.040 |
Why?
|
| Gene Expression Regulation | 1 | 2005 | 1293 | 0.040 |
Why?
|
| Rheumatology | 1 | 2000 | 46 | 0.040 |
Why?
|
| Stem Cell Factor | 2 | 2014 | 39 | 0.040 |
Why?
|
| Disabled Persons | 1 | 2000 | 94 | 0.040 |
Why?
|
| Physical Fitness | 1 | 2000 | 117 | 0.040 |
Why?
|
| Mice, Inbred NOD | 2 | 2014 | 138 | 0.040 |
Why?
|
| Motor Activity | 1 | 2003 | 621 | 0.040 |
Why?
|
| Benzamides | 2 | 2011 | 156 | 0.040 |
Why?
|
| Sequence Analysis, DNA | 3 | 2006 | 208 | 0.040 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2003 | 529 | 0.040 |
Why?
|
| Positron-Emission Tomography | 2 | 2011 | 160 | 0.040 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2000 | 157 | 0.040 |
Why?
|
| Comorbidity | 4 | 2007 | 1426 | 0.040 |
Why?
|
| Serine Endopeptidases | 2 | 2010 | 50 | 0.040 |
Why?
|
| HIV Infections | 2 | 2009 | 791 | 0.040 |
Why?
|
| Drug Therapy, Combination | 2 | 2012 | 649 | 0.040 |
Why?
|
| Area Under Curve | 2 | 2008 | 238 | 0.040 |
Why?
|
| Transplantation Conditioning | 2 | 2008 | 34 | 0.040 |
Why?
|
| District of Columbia | 2 | 2008 | 23 | 0.040 |
Why?
|
| Pain Measurement | 2 | 2009 | 328 | 0.040 |
Why?
|
| Drug Interactions | 2 | 2011 | 289 | 0.040 |
Why?
|
| Reference Values | 3 | 2003 | 579 | 0.040 |
Why?
|
| Advance Directives | 2 | 2007 | 22 | 0.030 |
Why?
|
| Blood Cell Count | 2 | 2009 | 35 | 0.030 |
Why?
|
| Tea | 1 | 2016 | 23 | 0.030 |
Why?
|
| Cross Reactions | 1 | 2016 | 57 | 0.030 |
Why?
|
| Antigens, Viral | 1 | 2016 | 35 | 0.030 |
Why?
|
| Viral Nonstructural Proteins | 1 | 2016 | 16 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2016 | 68 | 0.030 |
Why?
|
| Genetic Engineering | 1 | 2016 | 41 | 0.030 |
Why?
|
| Radiography | 3 | 2002 | 572 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2016 | 260 | 0.030 |
Why?
|
| Marijuana Abuse | 1 | 1999 | 251 | 0.030 |
Why?
|
| Interferon-gamma | 2 | 2007 | 241 | 0.030 |
Why?
|
| Chromatin Immunoprecipitation | 2 | 2005 | 52 | 0.030 |
Why?
|
| Acetylation | 2 | 2006 | 94 | 0.030 |
Why?
|
| Cell Death | 1 | 2016 | 329 | 0.030 |
Why?
|
| Lysosomal-Associated Membrane Protein 1 | 1 | 2015 | 8 | 0.030 |
Why?
|
| Molecular Targeted Therapy | 1 | 2016 | 170 | 0.030 |
Why?
|
| Allosteric Regulation | 1 | 2015 | 58 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2016 | 326 | 0.030 |
Why?
|
| Mental Disorders | 1 | 2000 | 659 | 0.030 |
Why?
|
| Health Status Indicators | 2 | 2009 | 117 | 0.030 |
Why?
|
| Hydroxamic Acids | 2 | 2006 | 84 | 0.030 |
Why?
|
| Reference Standards | 2 | 2008 | 115 | 0.030 |
Why?
|
| Cytotoxicity, Immunologic | 2 | 2006 | 66 | 0.030 |
Why?
|
| Melanoma, Experimental | 1 | 2015 | 95 | 0.030 |
Why?
|
| Amphiregulin | 1 | 2014 | 19 | 0.030 |
Why?
|
| Forkhead Box Protein O3 | 1 | 2014 | 10 | 0.030 |
Why?
|
| 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid | 1 | 2014 | 41 | 0.030 |
Why?
|
| Microscopy, Confocal | 1 | 2015 | 337 | 0.030 |
Why?
|
| Sex Factors | 3 | 2004 | 1266 | 0.030 |
Why?
|
| Genes, Tumor Suppressor | 2 | 2006 | 61 | 0.030 |
Why?
|
| Butadienes | 1 | 2014 | 26 | 0.030 |
Why?
|
| Trastuzumab | 1 | 2014 | 17 | 0.030 |
Why?
|
| Models, Organizational | 1 | 2015 | 97 | 0.030 |
Why?
|
| Injections, Subcutaneous | 2 | 2005 | 87 | 0.030 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2014 | 30 | 0.030 |
Why?
|
| Recombinant Proteins | 2 | 2007 | 742 | 0.030 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2014 | 19 | 0.030 |
Why?
|
| Monophenol Monooxygenase | 1 | 2014 | 8 | 0.030 |
Why?
|
| Hypersensitivity, Delayed | 1 | 2014 | 19 | 0.030 |
Why?
|
| Cell Division | 2 | 2008 | 541 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 2 | 2006 | 532 | 0.030 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2014 | 69 | 0.030 |
Why?
|
| Transgenes | 1 | 2014 | 92 | 0.030 |
Why?
|
| Spheroids, Cellular | 1 | 2014 | 45 | 0.030 |
Why?
|
| Likelihood Functions | 1 | 2014 | 106 | 0.030 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2014 | 35 | 0.030 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2003 | 1085 | 0.030 |
Why?
|
| Sirtuin 1 | 1 | 2014 | 47 | 0.030 |
Why?
|
| Cyclin D2 | 2 | 2004 | 5 | 0.030 |
Why?
|
| Organoplatinum Compounds | 1 | 2014 | 21 | 0.030 |
Why?
|
| Aggression | 1 | 2014 | 98 | 0.030 |
Why?
|
| Twist-Related Protein 1 | 2 | 2004 | 13 | 0.030 |
Why?
|
| Immunologic Memory | 1 | 2014 | 75 | 0.030 |
Why?
|
| Cell Differentiation | 2 | 2011 | 1034 | 0.030 |
Why?
|
| Cytoplasm | 1 | 2014 | 155 | 0.030 |
Why?
|
| Interleukin-17 | 1 | 2014 | 62 | 0.030 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2014 | 58 | 0.030 |
Why?
|
| Epitopes | 1 | 2014 | 146 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2014 | 174 | 0.030 |
Why?
|
| Superoxide Dismutase | 1 | 2014 | 149 | 0.030 |
Why?
|
| Caspase 3 | 1 | 2014 | 233 | 0.030 |
Why?
|
| Luciferases | 1 | 2013 | 105 | 0.030 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 1 | 2014 | 257 | 0.030 |
Why?
|
| Neoplastic Stem Cells | 1 | 2014 | 84 | 0.030 |
Why?
|
| Antidepressive Agents | 1 | 2015 | 216 | 0.030 |
Why?
|
| Green Fluorescent Proteins | 1 | 2013 | 200 | 0.030 |
Why?
|
| Organ Size | 1 | 2013 | 242 | 0.030 |
Why?
|
| MAP Kinase Signaling System | 1 | 2014 | 247 | 0.030 |
Why?
|
| Rats | 3 | 2007 | 5300 | 0.030 |
Why?
|
| Antigens | 1 | 2013 | 90 | 0.030 |
Why?
|
| Antigen-Presenting Cells | 1 | 2013 | 50 | 0.030 |
Why?
|
| Patient Care Team | 1 | 2015 | 311 | 0.030 |
Why?
|
| Fingolimod Hydrochloride | 1 | 2012 | 24 | 0.030 |
Why?
|
| Parathyroid Hormone | 2 | 2005 | 117 | 0.030 |
Why?
|
| Receptors, CXCR | 1 | 2012 | 2 | 0.030 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2007 | 245 | 0.030 |
Why?
|
| Health Status | 2 | 2008 | 429 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 2 | 2010 | 772 | 0.030 |
Why?
|
| Cyclin D1 | 1 | 2012 | 37 | 0.030 |
Why?
|
| International System of Units | 1 | 2012 | 6 | 0.030 |
Why?
|
| Mucositis | 1 | 2012 | 9 | 0.030 |
Why?
|
| Cytarabine | 1 | 2012 | 44 | 0.030 |
Why?
|
| Sleep | 1 | 2014 | 263 | 0.030 |
Why?
|
| Vincristine | 1 | 2012 | 44 | 0.030 |
Why?
|
| Lumbosacral Region | 2 | 2002 | 18 | 0.030 |
Why?
|
| Hospital Charges | 2 | 2003 | 60 | 0.030 |
Why?
|
| Angiopoietin-2 | 1 | 2012 | 5 | 0.030 |
Why?
|
| Swine | 1 | 2013 | 672 | 0.030 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2012 | 91 | 0.030 |
Why?
|
| Necrosis | 1 | 2012 | 239 | 0.030 |
Why?
|
| Sphingolipids | 1 | 2015 | 337 | 0.030 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2012 | 76 | 0.030 |
Why?
|
| Bevacizumab | 1 | 2012 | 34 | 0.030 |
Why?
|
| Brain | 1 | 2002 | 2176 | 0.030 |
Why?
|
| Flavonoids | 1 | 2012 | 109 | 0.020 |
Why?
|
| Piperidines | 1 | 2012 | 123 | 0.020 |
Why?
|
| Myelopoiesis | 1 | 2011 | 1 | 0.020 |
Why?
|
| Drug Monitoring | 1 | 2012 | 107 | 0.020 |
Why?
|
| Leukemia, Lymphoid | 1 | 2011 | 17 | 0.020 |
Why?
|
| Aromatase Inhibitors | 1 | 2011 | 17 | 0.020 |
Why?
|
| GPI-Linked Proteins | 1 | 2011 | 27 | 0.020 |
Why?
|
| CD11b Antigen | 1 | 2011 | 47 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2014 | 403 | 0.020 |
Why?
|
| Vaccination | 1 | 2013 | 189 | 0.020 |
Why?
|
| Glyoxylates | 1 | 2011 | 1 | 0.020 |
Why?
|
| Pseudopodia | 1 | 2011 | 16 | 0.020 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2012 | 223 | 0.020 |
Why?
|
| Bortezomib | 1 | 2011 | 45 | 0.020 |
Why?
|
| Androgen Antagonists | 1 | 2011 | 45 | 0.020 |
Why?
|
| Dendritic Cells | 1 | 2013 | 201 | 0.020 |
Why?
|
| Dogs | 1 | 2012 | 490 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2012 | 219 | 0.020 |
Why?
|
| Quality Improvement | 1 | 2015 | 413 | 0.020 |
Why?
|
| Zinc Finger E-box Binding Homeobox 2 | 1 | 2010 | 5 | 0.020 |
Why?
|
| Tumor Microenvironment | 1 | 2012 | 213 | 0.020 |
Why?
|
| Zinc Finger E-box-Binding Homeobox 1 | 1 | 2010 | 22 | 0.020 |
Why?
|
| Radiation Oncology | 1 | 2010 | 12 | 0.020 |
Why?
|
| Cell Hypoxia | 1 | 2011 | 92 | 0.020 |
Why?
|
| Dilatation, Pathologic | 2 | 2001 | 58 | 0.020 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2012 | 131 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2012 | 546 | 0.020 |
Why?
|
| Camptothecin | 1 | 2010 | 39 | 0.020 |
Why?
|
| Cognition | 2 | 2008 | 513 | 0.020 |
Why?
|
| Receptors, IgG | 1 | 2011 | 94 | 0.020 |
Why?
|
| Leukemia, Myeloid, Chronic-Phase | 1 | 2010 | 1 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 2011 | 765 | 0.020 |
Why?
|
| Protein Transport | 1 | 2011 | 280 | 0.020 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2010 | 35 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2010 | 216 | 0.020 |
Why?
|
| Endosonography | 1 | 2011 | 177 | 0.020 |
Why?
|
| K562 Cells | 1 | 2010 | 44 | 0.020 |
Why?
|
| Aminoquinolines | 1 | 2010 | 14 | 0.020 |
Why?
|
| Receptor, ErbB-3 | 1 | 2009 | 17 | 0.020 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2010 | 37 | 0.020 |
Why?
|
| Body Weight | 2 | 2003 | 554 | 0.020 |
Why?
|
| Ohio | 1 | 2009 | 64 | 0.020 |
Why?
|
| Interviews as Topic | 1 | 2011 | 392 | 0.020 |
Why?
|
| Peptides | 1 | 2013 | 455 | 0.020 |
Why?
|
| Skin | 1 | 2013 | 451 | 0.020 |
Why?
|
| Endpoint Determination | 1 | 2010 | 82 | 0.020 |
Why?
|
| Safety | 1 | 2010 | 145 | 0.020 |
Why?
|
| Repressor Proteins | 1 | 2010 | 183 | 0.020 |
Why?
|
| Stroke | 1 | 2002 | 2163 | 0.020 |
Why?
|
| Retreatment | 1 | 2009 | 59 | 0.020 |
Why?
|
| Clinical Protocols | 1 | 2010 | 172 | 0.020 |
Why?
|
| Models, Theoretical | 1 | 2012 | 384 | 0.020 |
Why?
|
| Thromboembolism | 1 | 2009 | 91 | 0.020 |
Why?
|
| Ethics, Research | 1 | 2009 | 12 | 0.020 |
Why?
|
| HL-60 Cells | 1 | 2008 | 50 | 0.020 |
Why?
|
| U937 Cells | 1 | 2008 | 61 | 0.020 |
Why?
|
| Jurkat Cells | 1 | 2008 | 59 | 0.020 |
Why?
|
| South Africa | 1 | 2009 | 45 | 0.020 |
Why?
|
| Radiometry | 1 | 2009 | 64 | 0.020 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2009 | 84 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2011 | 331 | 0.020 |
Why?
|
| Factor Analysis, Statistical | 1 | 2009 | 201 | 0.020 |
Why?
|
| Healthcare Disparities | 1 | 2012 | 378 | 0.020 |
Why?
|
| Treatment Refusal | 1 | 2009 | 40 | 0.020 |
Why?
|
| Mammography | 1 | 2011 | 310 | 0.020 |
Why?
|
| Pattern Recognition, Automated | 1 | 2009 | 70 | 0.020 |
Why?
|
| Social Class | 1 | 2009 | 127 | 0.020 |
Why?
|
| Age of Onset | 1 | 2008 | 188 | 0.020 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2009 | 53 | 0.020 |
Why?
|
| Thrombocytopenia | 1 | 2009 | 122 | 0.020 |
Why?
|
| Radiotherapy, Conformal | 1 | 2008 | 24 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2008 | 137 | 0.020 |
Why?
|
| Selection Bias | 1 | 2008 | 23 | 0.020 |
Why?
|
| Estramustine | 1 | 2008 | 35 | 0.020 |
Why?
|
| Androgens | 1 | 2008 | 41 | 0.020 |
Why?
|
| Age Distribution | 1 | 2009 | 320 | 0.020 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2007 | 3 | 0.020 |
Why?
|
| Serum | 1 | 2008 | 24 | 0.020 |
Why?
|
| DNA, Complementary | 1 | 2008 | 251 | 0.020 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2008 | 124 | 0.020 |
Why?
|
| Pregnancy | 2 | 2005 | 2334 | 0.020 |
Why?
|
| Phantoms, Imaging | 1 | 2009 | 189 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2008 | 411 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2008 | 219 | 0.020 |
Why?
|
| Meta-Analysis as Topic | 1 | 2007 | 57 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2007 | 159 | 0.020 |
Why?
|
| Hepatectomy | 1 | 2008 | 58 | 0.020 |
Why?
|
| Databases, Genetic | 1 | 2007 | 52 | 0.020 |
Why?
|
| Genome, Human | 1 | 2007 | 62 | 0.020 |
Why?
|
| Hyperparathyroidism, Primary | 1 | 2007 | 14 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2009 | 504 | 0.020 |
Why?
|
| NAD(P)H Dehydrogenase (Quinone) | 1 | 2007 | 3 | 0.020 |
Why?
|
| Liver Function Tests | 1 | 2008 | 114 | 0.020 |
Why?
|
| Hyperplasia | 1 | 2007 | 89 | 0.020 |
Why?
|
| Injections, Intralesional | 1 | 2007 | 25 | 0.020 |
Why?
|
| Gastrostomy | 1 | 2008 | 110 | 0.020 |
Why?
|
| Sulfoxides | 1 | 2007 | 16 | 0.020 |
Why?
|
| Macaca fascicularis | 1 | 2007 | 31 | 0.020 |
Why?
|
| Isothiocyanates | 1 | 2007 | 10 | 0.020 |
Why?
|
| Ethics Committees | 1 | 2007 | 4 | 0.020 |
Why?
|
| Glutathione S-Transferase pi | 1 | 2007 | 53 | 0.020 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2007 | 35 | 0.020 |
Why?
|
| Neuropsychological Tests | 1 | 2009 | 517 | 0.020 |
Why?
|
| Tubulin | 1 | 2007 | 60 | 0.020 |
Why?
|
| Heme Oxygenase-1 | 1 | 2007 | 40 | 0.020 |
Why?
|
| Syndrome | 1 | 2007 | 255 | 0.020 |
Why?
|
| HSP40 Heat-Shock Proteins | 1 | 2006 | 8 | 0.020 |
Why?
|
| Saliva | 1 | 2008 | 142 | 0.020 |
Why?
|
| Diet Surveys | 1 | 2006 | 24 | 0.020 |
Why?
|
| Enteral Nutrition | 1 | 2008 | 157 | 0.020 |
Why?
|
| Bias | 1 | 2007 | 148 | 0.020 |
Why?
|
| Tissue Distribution | 1 | 2007 | 282 | 0.020 |
Why?
|
| Switzerland | 1 | 2006 | 4 | 0.020 |
Why?
|
| Poverty Areas | 1 | 2006 | 20 | 0.020 |
Why?
|
| Professional Autonomy | 1 | 2006 | 24 | 0.020 |
Why?
|
| Norway | 1 | 2006 | 18 | 0.020 |
Why?
|
| Inflammation | 1 | 2013 | 1030 | 0.020 |
Why?
|
| Colectomy | 1 | 2007 | 64 | 0.020 |
Why?
|
| Italy | 1 | 2006 | 36 | 0.020 |
Why?
|
| Patient Advocacy | 1 | 2006 | 40 | 0.020 |
Why?
|
| Genomics | 1 | 2007 | 168 | 0.020 |
Why?
|
| Europe | 1 | 2007 | 196 | 0.020 |
Why?
|
| Mutation | 2 | 2002 | 1213 | 0.020 |
Why?
|
| Resource Allocation | 1 | 2006 | 35 | 0.020 |
Why?
|
| Registries | 1 | 2009 | 733 | 0.020 |
Why?
|
| Dietary Fats | 1 | 2006 | 103 | 0.020 |
Why?
|
| Conflict of Interest | 1 | 2006 | 48 | 0.020 |
Why?
|
| Drug Administration Routes | 1 | 2006 | 25 | 0.020 |
Why?
|
| Radiation Dosage | 1 | 2009 | 419 | 0.020 |
Why?
|
| United Kingdom | 1 | 2006 | 152 | 0.020 |
Why?
|
| Vidarabine | 1 | 2005 | 12 | 0.020 |
Why?
|
| Physicians, Family | 1 | 2006 | 83 | 0.020 |
Why?
|
| HCT116 Cells | 1 | 2006 | 63 | 0.020 |
Why?
|
| Kinetics | 1 | 2007 | 1047 | 0.020 |
Why?
|
| Adaptation, Psychological | 1 | 2009 | 447 | 0.020 |
Why?
|
| Hepatocyte Nuclear Factor 4 | 1 | 2005 | 28 | 0.020 |
Why?
|
| Amniotic Fluid | 1 | 2005 | 30 | 0.020 |
Why?
|
| Patient Care Planning | 1 | 2006 | 108 | 0.020 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2006 | 100 | 0.020 |
Why?
|
| Blotting, Northern | 1 | 2005 | 189 | 0.020 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2006 | 65 | 0.020 |
Why?
|
| Neoadjuvant Therapy | 1 | 2006 | 104 | 0.020 |
Why?
|
| Microarray Analysis | 1 | 2005 | 63 | 0.020 |
Why?
|
| Brain Mapping | 1 | 2008 | 532 | 0.020 |
Why?
|
| Caspases | 1 | 2006 | 194 | 0.020 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2005 | 98 | 0.020 |
Why?
|
| Apolipoprotein C-I | 1 | 2005 | 2 | 0.020 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2005 | 85 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 2005 | 215 | 0.020 |
Why?
|
| Interpersonal Relations | 1 | 2007 | 209 | 0.020 |
Why?
|
| Longevity | 1 | 2005 | 60 | 0.020 |
Why?
|
| Chemokines, C | 1 | 2004 | 1 | 0.020 |
Why?
|
| beta-Galactosidase | 1 | 2005 | 88 | 0.020 |
Why?
|
| DNA Modification Methylases | 1 | 2004 | 24 | 0.020 |
Why?
|
| Rabbits | 1 | 2005 | 509 | 0.020 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2006 | 216 | 0.020 |
Why?
|
| Particle Size | 1 | 2005 | 201 | 0.020 |
Why?
|
| Granulocytes | 1 | 2004 | 22 | 0.020 |
Why?
|
| Sulfates | 1 | 2004 | 28 | 0.020 |
Why?
|
| Allelic Imbalance | 1 | 2004 | 3 | 0.020 |
Why?
|
| Quality Control | 1 | 2004 | 81 | 0.020 |
Why?
|
| Cloning, Molecular | 1 | 2005 | 357 | 0.010 |
Why?
|
| Body Constitution | 1 | 2004 | 24 | 0.010 |
Why?
|
| Clone Cells | 1 | 2004 | 67 | 0.010 |
Why?
|
| Gene Amplification | 1 | 2004 | 71 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2004 | 56 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 22 | 1 | 2004 | 18 | 0.010 |
Why?
|
| Gene Dosage | 1 | 2004 | 47 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2005 | 322 | 0.010 |
Why?
|
| Apolipoprotein C-II | 1 | 2004 | 2 | 0.010 |
Why?
|
| Apolipoprotein A-II | 1 | 2004 | 3 | 0.010 |
Why?
|
| Plasmids | 1 | 2005 | 258 | 0.010 |
Why?
|
| Remission, Spontaneous | 1 | 2004 | 25 | 0.010 |
Why?
|
| Gene Deletion | 1 | 2005 | 235 | 0.010 |
Why?
|
| Early Detection of Cancer | 1 | 2009 | 454 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 2004 | 201 | 0.010 |
Why?
|
| Apolipoprotein A-I | 1 | 2004 | 29 | 0.010 |
Why?
|
| Cost Control | 1 | 2004 | 34 | 0.010 |
Why?
|
| Drugs, Generic | 1 | 2004 | 17 | 0.010 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2004 | 116 | 0.010 |
Why?
|
| Cholesterol, HDL | 1 | 2004 | 112 | 0.010 |
Why?
|
| Multigene Family | 1 | 2003 | 93 | 0.010 |
Why?
|
| Ubiquitins | 1 | 2003 | 22 | 0.010 |
Why?
|
| Immunization Schedule | 1 | 2003 | 25 | 0.010 |
Why?
|
| Lymphocyte Count | 1 | 2003 | 53 | 0.010 |
Why?
|
| Blood Glucose Self-Monitoring | 1 | 2003 | 62 | 0.010 |
Why?
|
| 3T3 Cells | 1 | 2003 | 124 | 0.010 |
Why?
|
| Claudins | 1 | 2003 | 6 | 0.010 |
Why?
|
| Binding Sites | 1 | 2005 | 631 | 0.010 |
Why?
|
| Lipids | 1 | 2005 | 298 | 0.010 |
Why?
|
| Adjuvants, Immunologic | 1 | 2003 | 63 | 0.010 |
Why?
|
| Membrane Glycoproteins | 1 | 2006 | 370 | 0.010 |
Why?
|
| Hydrolysis | 1 | 2003 | 144 | 0.010 |
Why?
|
| Alzheimer Disease | 1 | 2008 | 565 | 0.010 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2003 | 29 | 0.010 |
Why?
|
| Cholesterol, LDL | 1 | 2004 | 161 | 0.010 |
Why?
|
| Irritable Mood | 1 | 2003 | 15 | 0.010 |
Why?
|
| Amylases | 1 | 2003 | 17 | 0.010 |
Why?
|
| Actins | 1 | 2004 | 249 | 0.010 |
Why?
|
| Infant, Premature | 1 | 2005 | 284 | 0.010 |
Why?
|
| Health Care Surveys | 1 | 2004 | 239 | 0.010 |
Why?
|
| Thrombosis | 1 | 2004 | 218 | 0.010 |
Why?
|
| Choline | 1 | 2002 | 14 | 0.010 |
Why?
|
| Erythema | 1 | 2002 | 18 | 0.010 |
Why?
|
| Preoperative Care | 1 | 2004 | 275 | 0.010 |
Why?
|
| Creatine | 1 | 2002 | 30 | 0.010 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2003 | 63 | 0.010 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2003 | 70 | 0.010 |
Why?
|
| Gene Silencing | 1 | 2003 | 137 | 0.010 |
Why?
|
| Culture Media, Serum-Free | 1 | 2002 | 35 | 0.010 |
Why?
|
| Thrombopoietin | 1 | 2002 | 15 | 0.010 |
Why?
|
| Diarrhea | 1 | 2002 | 63 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2005 | 1447 | 0.010 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 2002 | 32 | 0.010 |
Why?
|
| Colony-Forming Units Assay | 1 | 2002 | 78 | 0.010 |
Why?
|
| Genes, APC | 1 | 2002 | 15 | 0.010 |
Why?
|
| Surgical Procedures, Operative | 1 | 2003 | 124 | 0.010 |
Why?
|
| Knee Joint | 1 | 2003 | 115 | 0.010 |
Why?
|
| Health Facility Size | 1 | 2002 | 2 | 0.010 |
Why?
|
| Antigens, CD34 | 1 | 2002 | 75 | 0.010 |
Why?
|
| Prostaglandins | 1 | 2002 | 65 | 0.010 |
Why?
|
| Mexican Americans | 1 | 2002 | 30 | 0.010 |
Why?
|
| Thromboxane B2 | 1 | 2002 | 108 | 0.010 |
Why?
|
| Guideline Adherence | 1 | 2004 | 287 | 0.010 |
Why?
|
| Long-Term Care | 1 | 2002 | 53 | 0.010 |
Why?
|
| Platelet Transfusion | 1 | 2002 | 21 | 0.010 |
Why?
|
| Rectum | 1 | 2002 | 62 | 0.010 |
Why?
|
| Muscle Contraction | 1 | 2003 | 210 | 0.010 |
Why?
|
| Cell Separation | 1 | 2002 | 132 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2007 | 2083 | 0.010 |
Why?
|
| Cell Adhesion | 1 | 2003 | 324 | 0.010 |
Why?
|
| Plasma | 1 | 2002 | 58 | 0.010 |
Why?
|
| Brain Diseases | 1 | 2002 | 78 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 2005 | 597 | 0.010 |
Why?
|
| Tyrphostins | 1 | 2001 | 13 | 0.010 |
Why?
|
| Hospital Costs | 1 | 2002 | 117 | 0.010 |
Why?
|
| Cell Lineage | 1 | 2002 | 146 | 0.010 |
Why?
|
| Tandem Repeat Sequences | 1 | 2001 | 13 | 0.010 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 1 | 2001 | 21 | 0.010 |
Why?
|
| Sleep Wake Disorders | 1 | 2002 | 94 | 0.010 |
Why?
|
| Africa | 1 | 2001 | 41 | 0.010 |
Why?
|
| User-Computer Interface | 1 | 2003 | 230 | 0.010 |
Why?
|
| Lipoproteins, LDL | 1 | 2004 | 343 | 0.010 |
Why?
|
| Body Height | 1 | 2001 | 67 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2006 | 1330 | 0.010 |
Why?
|
| Osteocalcin | 1 | 2000 | 37 | 0.010 |
Why?
|
| Spondylolisthesis | 1 | 2001 | 20 | 0.010 |
Why?
|
| Kidney | 1 | 2005 | 945 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2004 | 1140 | 0.010 |
Why?
|
| Hemoglobins | 1 | 2001 | 120 | 0.010 |
Why?
|
| Nutrition Surveys | 1 | 2002 | 208 | 0.010 |
Why?
|
| Heart Rate | 1 | 2003 | 568 | 0.010 |
Why?
|
| Epithelial Cells | 1 | 2003 | 431 | 0.010 |
Why?
|
| Nutritional Status | 1 | 2001 | 112 | 0.010 |
Why?
|
| Software | 1 | 2003 | 418 | 0.010 |
Why?
|
| Diabetes Complications | 1 | 2002 | 249 | 0.010 |
Why?
|
| Antirheumatic Agents | 1 | 2000 | 59 | 0.010 |
Why?
|
| Patient Discharge | 1 | 2002 | 294 | 0.010 |
Why?
|
| Survivors | 1 | 2002 | 256 | 0.010 |
Why?
|
| Task Performance and Analysis | 1 | 2000 | 150 | 0.010 |
Why?
|
| Hypertension | 1 | 2009 | 1535 | 0.010 |
Why?
|
| Mental Status Schedule | 1 | 1999 | 31 | 0.010 |
Why?
|
| Cell Survival | 1 | 2002 | 901 | 0.010 |
Why?
|
| Forms and Records Control | 1 | 1999 | 16 | 0.010 |
Why?
|
| Patient Compliance | 1 | 2002 | 402 | 0.010 |
Why?
|
| Morbidity | 1 | 1999 | 130 | 0.010 |
Why?
|
| Cardiovascular Diseases | 1 | 2005 | 940 | 0.010 |
Why?
|
| Cannabis | 1 | 1999 | 115 | 0.010 |
Why?
|
| Calcium | 1 | 2000 | 929 | 0.010 |
Why?
|
| Emergency Service, Hospital | 1 | 2002 | 711 | 0.010 |
Why?
|
| Spinal Cord Injuries | 1 | 2001 | 551 | 0.010 |
Why?
|
| Mass Screening | 1 | 2001 | 843 | 0.010 |
Why?
|